{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:43:24Z","timestamp":1792035804325,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.virol.2023.06.002","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T06:34:34Z","timestamp":1686638074000},"page":"179-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines"],"prefix":"10.1016","volume":"585","author":[{"given":"Alekxander","family":"Binderup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fossat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Fernandez-Antunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte S.","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizandro Ren\u00e9","family":"Rivera-Rangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troels K.H.","family":"Scheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Fahn\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3699-1814","authenticated-orcid":false,"given":"Santseharay","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2023.06.002_bib1","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1016\/j.bmcl.2017.08.029","article-title":"The discovery of IDX21437: design, synthesis and antiviral evaluation of 2\u2019-\u03b1-chloro-2\u2019-\u03b2-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors","volume":"27","author":"Alexandre","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.virol.2023.06.002_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02587-17","article-title":"Sofosbuvir and ribavirin liver pharmacokinetics in patients infected with hepatitis C virus","volume":"62","author":"Babusis","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.06.002_bib3","first-page":"3751","article-title":"Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones","volume":"38","author":"Biedler","year":"1978","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2023.06.002_bib4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrd.2017.33","article-title":"Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond","volume":"16","author":"Boldescu","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.virol.2023.06.002_bib6","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3390\/v13112164","article-title":"IRE1-Mediated unfolded protein response promotes the replication of tick-borne flaviviruses in a virus and cell-type dependent manner","volume":"13","author":"Breitkopf","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2023.06.002_bib7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/ph13120460","article-title":"Anti-tick-borne encephalitis virus activity of novel uridine glycoconjugates containing amide or\/and 1,2,3-triazole moiety in the linker structure","volume":"13","author":"Brzuska","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.virol.2023.06.002_bib8","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2023.06.002_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Bullard-Feibelman","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.06.002_bib10","doi-asserted-by":"crossref","first-page":"11979","DOI":"10.1074\/jbc.M210914200","article-title":"Inhibition of hepatitis C virus RNA replication by 2\u2019-modified nucleoside analogs","volume":"278","author":"Carroll","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2023.06.002_bib11","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.sbi.2009.10.015","article-title":"RNA-dependent RNA polymerases from Flaviviridae","volume":"19","author":"Choi","year":"2009","journal-title":"Curr. Opin. Struct. Biol., Catalysis and regulation\/Proteins"},{"key":"10.1016\/j.virol.2023.06.002_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.779014","article-title":"Case report: yellow fever vaccine-associated neurotropic disease and associated MRI, EEG, and CSF findings","volume":"12","author":"Cohen","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.virol.2023.06.002_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0166-3542(02)00185-7","article-title":"Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses","volume":"58","author":"Crance","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.06.002_bib14","series-title":"Antiviral Strategies, Handbook of Experimental Pharmacology","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-540-79086-0_3","article-title":"Antiviral agents acting as DNA or RNA chain terminators","author":"De Clercq","year":"2009"},{"key":"10.1016\/j.virol.2023.06.002_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007072","article-title":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo","volume":"13","author":"de Freitas","year":"2019","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.virol.2023.06.002_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104708","article-title":"Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro","volume":"175","author":"Dragoni","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.06.002_bib17","series-title":"Eur. Cent. Dis. Prev. Control","year":"2015"},{"key":"10.1016\/j.virol.2023.06.002_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01028-17","article-title":"Escape of tick-borne flavivirus from 2\u2032-C-methylated nucleoside antivirals is mediated by a single conservative mutation in NS5 that has a dramatic effect on viral fitness","volume":"91","author":"Eyer","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2023.06.002_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/2040206618761299","article-title":"Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses","volume":"26","author":"Eyer","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.virol.2023.06.002_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2016.07.018","article-title":"Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus","volume":"133","author":"Eyer","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.06.002_bib21","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.00807-15","article-title":"Nucleoside inhibitors of tick-borne encephalitis virus","volume":"59","author":"Eyer","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.06.002_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2017.03.012","article-title":"Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses","volume":"142","author":"Eyer","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.06.002_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-4939-8976-8_5","article-title":"Full-Length open reading frame amplification of hepatitis C virus","author":"Fahn\u00f8e","year":"2019","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"10.1016\/j.virol.2023.06.002_bib24","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1128\/AAC.02351-13","article-title":"Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug","volume":"58","author":"Feng","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.06.002_bib25","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1038\/s41598-017-09797-8","article-title":"Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae","volume":"7","author":"Ferreira","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2023.06.002_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027207","article-title":"Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled trial in Brazil (SOFFA study)","volume":"9","author":"Figueiredo-Mello","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.virol.2023.06.002_bib27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/cbdd.13091","article-title":"Sofosbuvir as treatment against dengue?","volume":"91","author":"Gan","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.virol.2023.06.002_bib28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S2468-1253(17)30159-0","volume":"2","author":"Gane","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.virol.2023.06.002_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104859","article-title":"Sofosbuvir shows a protective effect against vertical transmission of Zika virus and the associated congenital syndrome in rhesus monkeys","volume":"182","author":"Gardinali","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.06.002_bib30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cll.2010.01.001","article-title":"Yellow fever: a reemerging threat","volume":"30","author":"Gardner","year":"2010","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.virol.2023.06.002_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.virol.2020.03.006","article-title":"An RNA-dependent RNA polymerase inhibitor for tick-borne encephalitis virus","volume":"546","author":"Gejji","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.virol.2023.06.002_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00988-21","article-title":"Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.06.002_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101529","article-title":"Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir","volume":"298","author":"Gordon","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2023.06.002_bib34","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1128\/JVI.02667-09","article-title":"Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies","volume":"84","author":"Gottwein","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2023.06.002_bib35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2217\/17460794.3.6.553","article-title":"Therapeutically targeting RNA viruses via lethal mutagenesis","volume":"3","author":"Graci","year":"2008","journal-title":"Future Virol."},{"key":"10.1016\/j.virol.2023.06.002_bib36","doi-asserted-by":"crossref","first-page":"10774","DOI":"10.1128\/JVI.01253-16","article-title":"A novel benzodiazepine compound inhibits yellow fever virus infection by specifically targeting NS4B protein","volume":"90","author":"Guo","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2023.06.002_bib37","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1021\/jm701260b","article-title":"Prodrugs of phosphates and phosphonates","volume":"51","author":"Hecker","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2023.06.002_bib38","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cts.12840","article-title":"Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID\u201019, in healthy subjects","volume":"13","author":"Humeniuk","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.virol.2023.06.002_bib39","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00005072-198509000-00003","article-title":"Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice","volume":"44","author":"Jacobsen","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.virol.2023.06.002_bib40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/hep.30647","article-title":"Evolutionary pathways to persistence of highly fit and resistant hepatitis C virus protease inhibitor escape variants","volume":"70","author":"Jensen","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2023.06.002_bib41","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1128\/AAC.03368-14","article-title":"BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model","volume":"58","author":"Julander","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.06.002_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105180","article-title":"An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral","volume":"195","author":"Julander","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.06.002_bib43","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1128\/AAC.01494-06","article-title":"Activity of T-1106 in a hamster model of yellow fever virus infection","volume":"51","author":"Julander","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.06.002_bib44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.antiviral.2010.03.004","article-title":"Efficacy of 2\u2032-C-methylcytidine against yellow fever virus in cell culture and in a hamster model","volume":"86","author":"Julander","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.06.002_bib45","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106","volume":"53","author":"Julander","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.06.002_bib46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/JVI.01399-12","article-title":"Japanese encephalitis virus infects neuronal cells through a clathrin-independent endocytic mechanism","volume":"87","author":"Kalia","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2023.06.002_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010291","article-title":"Finding a chink in the armor: update, limitations, and challenges toward successful antivirals against flaviviruses","volume":"16","author":"Komarasamy","year":"2022","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.virol.2023.06.002_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104899","article-title":"Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses","volume":"182","author":"Konkolova","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.06.002_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205294","article-title":"Evaluation of antivirals against tick-borne encephalitis virus in organotypic brain slices of rat cerebellum","volume":"13","author":"Lenz","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2023.06.002_bib50","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(08)60800-4","article-title":"Tick-borne encephalitis, the lancet","volume":"371","author":"Lindquist","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2023.06.002_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2023.06.002_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01537-21","article-title":"Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)","volume":"9","author":"Lo","year":"2021","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.virol.2023.06.002_bib53","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1099\/0022-1317-78-5-1049","article-title":"Infectious cDNA clones of tick-borne encephalitis virus European subtype prototypic strain Neudoerfl and high virulence strain Hypr","volume":"78","author":"Mandl","year":"1997","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2023.06.002_bib54","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.aohep.2019.09.001","article-title":"Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure","volume":"18","author":"Mendes","year":"2019","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.virol.2023.06.002_bib55","unstructured":"Merck Sharp & Dohme LLC, 2018. Single and Multiple Dose Study of Uprifosbuvir (MK-3682\/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)(Clinical Trial Registration No. results\/NCT01974687)(ClinicalTrials.gov)."},{"key":"10.1016\/j.virol.2023.06.002_bib56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.antiviral.2017.09.004","article-title":"Cell-line dependent antiviral activity of sofosbuvir against Zika virus","volume":"146","author":"Mumtaz","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.06.002_bib57","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1517\/17425240902824808","article-title":"Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues","volume":"6","author":"Peterson","year":"2009","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.virol.2023.06.002_bib58","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","article-title":"The continued threat of emerging flaviviruses","volume":"5","author":"Pierson","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.virol.2023.06.002_bib59","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1016\/j.bmc.2018.05.034","article-title":"Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs","volume":"26","author":"Pileggi","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.virol.2023.06.002_bib60","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1038\/s41598-023-29517-9","article-title":"Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro","volume":"13","author":"Radoshitzky","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2023.06.002_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00097-21","article-title":"Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication","volume":"65","author":"Ramirez","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.06.002_bib62","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1053\/j.gastro.2016.07.013","article-title":"Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir","volume":"151","author":"Ramirez","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2023.06.002_bib63","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3201\/eid2706.204170","article-title":"Neurologic disease after yellow fever vaccination, s\u00e3o paulo, Brazil, 2017-2018","volume":"27","author":"Ribeiro","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virol.2023.06.002_bib64","first-page":"223","article-title":"Tick-borne encephalitis: pathogenesis and clinical implications","volume":"8","author":"R\u016f\u017eek","year":"2010","journal-title":"Travel Med. Infect. Dis., Including a Special Issue on Tick-borne Encephalitis"},{"key":"10.1016\/j.virol.2023.06.002_bib65","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1099\/vir.0.010058-0","article-title":"Morphological changes in human neural cells following tick-borne encephalitis virus infection","volume":"90","author":"R\u016f\u017eek","year":"2009","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2023.06.002_bib73","doi-asserted-by":"crossref","first-page":"104939","DOI":"10.1016\/j.antiviral.2020.104939","article-title":"Generation of a reporter yellow fever virus for high throughput antiviral assays","volume":"183","author":"Sanchez-Velazquez","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virol.2023.06.002_bib66","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2-d-2\u2019-deoxy-2\u2019-\u03b1-fluoro-2\u2019-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2023.06.002_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100045","article-title":"Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside","volume":"2","author":"Tao","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.virol.2023.06.002_bib68","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.virol.2023.06.002_bib69","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.virol.2023.06.002_bib71","article-title":"Nucleoside analogs with antiviral activity against yellow fever virus","volume":"63","author":"Zandi","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.06.002_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.719308","article-title":"Drug-induced liver disturbance during the treatment of COVID-19","volume":"12","author":"Zhai","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682223001265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682223001265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T15:18:48Z","timestamp":1722611928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682223001265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":71,"alternative-id":["S0042682223001265"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2023.06.002","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2023.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}